What is true about Von Willebrand factor disease type IIB?

What is true about Von Willebrand factor disease type IIB?

• A. Decreased large multimers with normal platelet count
• B. Decreased large multimers and decreased platelet count
• C. Increased large multimers with decreased platelet count
• D. No change in multimeric forms or platelet count

Answer: (B)

Von Willebrand factor (vWF) disease type IIB is characterized by a distinct pathology involving the vWF's ability to mediate platelet adhesion. In this type of the disease, there is not only a reduction in the quantity of the large multimers of vWF, but this is accompanied by a decrease in the platelet count. The reason for the decrease in large multimers is due to increased binding of the vWF to platelets, which results in the aggregation of platelets. This aggregation leads to the consumption of platelets in the circulation, thereby resulting in thrombocytopenia, or a decreased platelet count. The significant aspect of vWF type IIB is the alteration in the vWF multimers and its interaction with platelets, which is more severe than in other types of Von Willebrand disease, where multimers may either be normal or increased. Understanding the pathophysiology behind this type can aid in recognizing the hematologic implications and potential treatment approaches for patients with vWF disease type IIB. Therefore, the combination of decreased large multimers and decreased platelet count highlights the underlying mechanism of the disease.

Von Willebrand factor (vWF) disease type IIB is characterized by a distinct pathology involving the vWF's ability to mediate platelet adhesion. In this type of the disease, there is not only a reduction in the quantity of the large multimers of vWF, but this is accompanied by a decrease in the platelet count.

The reason for the decrease in large multimers is due to increased binding of the vWF to platelets, which results in the aggregation of platelets. This aggregation leads to the consumption of platelets in the circulation, thereby resulting in thrombocytopenia, or a decreased platelet count. The significant aspect of vWF type IIB is the alteration in the vWF multimers and its interaction with platelets, which is more severe than in other types of Von Willebrand disease, where multimers may either be normal or increased.

Understanding the pathophysiology behind this type can aid in recognizing the hematologic implications and potential treatment approaches for patients with vWF disease type IIB. Therefore, the combination of decreased large multimers and decreased platelet count highlights the underlying mechanism of the disease.